Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth With a High-Quality Technical Setup
Protagonist Therapeutics Inc PTGX
$141.86
▲ +3.29%
(+$4.52)
⬆️ Above Yest. High
Open
$141.81
Prev Close
$137.34
Day Range
$138.23 – $143.45
52W Range
$62.24 – $160.81
Market Cap
$9.18B
P/E (TTM)
111.34
Beta
1.18
EPS (TTM)
$1.04
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-08-11 |
| Shares Out. | 64,310,000 |
| Website | protagonist-inc.com/ ↗ |
| Phone | 13026365401 |
| Employees | 141 |
| Revenue | $213.5M |
| Gross Profit | $213.5M |
| Net Income | $162.8M |
| Total Assets | $885.5M |
| Total Liabilities | $44.0M |
| Equity | $841.5M |
About Protagonist Therapeutics Inc
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Protagonist Therapeutics Inc is a publicly traded company under the ticker symbol PTGX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-09-01)